Skip to main content

Table 3 Demographic and clinical characteristics of study participants by treatment* experience

From: Assessment of motivating factors associated with the initiation and completion of treatment for chronic hepatitis C virus (HCV) infection

Patient characteristics

All (n = 120)

Completed (n = 30)

Discontinued (n = 30)

Current (n = 30)

Naïve (n = 30)

Age in years, mean(±SD)

49.1 (±11.6)

56.8 (±8.4)

49.9 (±9.6)

47.6 (±9.7)

42.0 (±13.2)

Male, n (%)

67 (56)

17 (57)

16 (53)

17 (57)

17 (57)

Married, n (%)

29 (24)

11 (37)

8 (27)

7 (23)

3 (10)

Living alone at time of treatment, n (%)a

34 (38)

12 (40)

10 (33)

12 (40)

NA

Race/ethnicity, n (%) b

Caucasian/White

76 (63)

25 (83)

16 (53)

22 (73)

13 (43)

African American/Black

28 (23)

3 (10)

8 (27)

6 (20)

11 (37)

Hispanic/Latino

12 (10)

2 (7)

5 (17)

1 (3)

4 (13)

Asian/Native Hawaiian/Other Pacific Islander

3 (3)

0 (0)

1 (3)

1 (3)

1 (3)

American Indian/Alaskan Native

1 (1)

0 (0)

0 (0)

1 (3)

0 (0)

Other

1 (1)

0 (0)

0 (0)

0 (0)

1 (3)

Highest education level, n (%) b

Bachelors/graduate degree

28 (23)

11 (37)

8 (27)

6 (20)

3 (10)

Some college/2 year associate degree

50 (42)

11 (37)

13 (43)

13 (43)

13 (43)

High school diploma/GED

32 (27)

7 (23)

7 (23)

10 (33)

8 (27)

Less than high school

10 (8)

1 (3)

1 (7)

1 (3)

6 (20)

Health insurance status when deciding whether to start treatment , n(%) c

Private

61 (51)

19 (63)

19 (63)

13 (43)

10 (33)

No health insurance

26 (22)

4 (13)

4 (13)

9 (30)

9 (30)

Medicaid only

19 (16)

3 (10)

6 (20)

5 (17)

5 (17)

Medicare or Medicaid/Medicare dual

9 (8)

2 (7)

1 (3)

1 (3)

5 (17)

Military insurance/TRICARE/VA

5 (4)

2 (7)

0 (0)

2 (7)

1 (3)

Comorbid conditions, n (%) d

Depression

62 (52)

10 (33)

16 (53)

19 (63)

17 (57)

Anxiety

53 (44)

9 (30)

11 (37)

15 (50)

18 (60)

Compensated cirrhosis

18 (15)

5 (17)

8 (27)

4 (13)

1 (3)

Diabetes

9 (8)

3 (10)

4 (13)

1 (3)

1 (3)

Time since HCV diagnosis in years, mean (±SD)

7.3 (±5.7)

10.4 (±6.4)

9.1 (±5.0)

5.4 (±5.5)

4.2 (±3.2)

  1. *Treatment refers to pegylated interferon and ribavirin (PR).
  2. aLiving alone at the time of treatment was not assessed for the treatment-naïve population, therefore the total denominator for all patients = 90.
  3. bPercentages may not add to 100% because of rounding.
  4. cCurrent health insurance status (i.e., status at the time of the interview) is captured for treatment-naïve patients.
  5. dPatients may have more than one comorbid condition.